×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SGMO – sangamo therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SGMO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/19
04:30 pm
sgmo
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain [Yahoo! Finance]
High
Report
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain [Yahoo! Finance]
11/19
04:15 pm
sgmo
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Medium
Report
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
11/15
06:15 am
sgmo
Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/15
12:02 am
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/14
01:34 pm
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/14
10:12 am
sgmo
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target raised by analysts at Barclays PLC from $3.00 to $9.00. They now have an "overweight" rating on the stock.
Medium
Report
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target raised by analysts at Barclays PLC from $3.00 to $9.00. They now have an "overweight" rating on the stock.
11/12
07:04 pm
sgmo
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates [Yahoo! Finance]
11/12
04:41 pm
sgmo
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results [Yahoo! Finance]
Medium
Report
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
04:01 pm
sgmo
sangamo therapeutics, inc.
BEAT
Report
-12.9%
sangamo therapeutics, inc.
8/6/2024
04:01 pm
sgmo
sangamo therapeutics, inc.
MISS
Report
-11.7%
sangamo therapeutics, inc.
5/9/2024
04:01 pm
sgmo
sangamo therapeutics, inc.
MISS
Report
7.3%
sangamo therapeutics, inc.
3/13/2024
08:05 am
sgmo
sangamo therapeutics, inc.
MISS
Report
-17.2%
sangamo therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/20
06:02 am
sgmo
Form EFFECT SANGAMO THERAPEUTICS,
High
Report
Form EFFECT SANGAMO THERAPEUTICS,
11/12
05:26 pm
sgmo
Form S-8 SANGAMO THERAPEUTICS,
High
Report
Form S-8 SANGAMO THERAPEUTICS,
11/12
05:24 pm
sgmo
Form S-3 SANGAMO THERAPEUTICS,
High
Report
Form S-3 SANGAMO THERAPEUTICS,
11/12
04:54 pm
sgmo
Form SC 13G/A SANGAMO THERAPEUTICS, Filed by: VANGUARD GROUP INC
High
Report
Form SC 13G/A SANGAMO THERAPEUTICS, Filed by: VANGUARD GROUP INC
11/12
04:03 pm
sgmo
Form 10-Q SANGAMO THERAPEUTICS, For: Sep 30
Medium
Report
Form 10-Q SANGAMO THERAPEUTICS, For: Sep 30
11/12
04:02 pm
sgmo
Form 8-K SANGAMO THERAPEUTICS, For: Nov 12
High
Report
Form 8-K SANGAMO THERAPEUTICS, For: Nov 12
11/4
01:55 pm
sgmo
Form SC 13G/A SANGAMO THERAPEUTICS, Filed by: VANGUARD GROUP INC
Medium
Report
Form SC 13G/A SANGAMO THERAPEUTICS, Filed by: VANGUARD GROUP INC
10/28
04:12 pm
sgmo
Form 3 SANGAMO THERAPEUTICS, For: Oct 18 Filed by: Davis Gregory D
Medium
Report
Form 3 SANGAMO THERAPEUTICS, For: Oct 18 Filed by: Davis Gregory D
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/27
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
33.3%
4/2 Form DEF 14A SANGAMO THERAPEUTICS, For: May 18 8.8%
4/17 Form 8-K SANGAMO THERAPEUTICS, For: Apr 13 8.6%
3/16 Sangamo's Partnership With Biogen Is Only One Big Pharma Partnership Based Off Of Pipeline [Seeking Alpha] 8.2%
3/18 Form 4 SANGAMO THERAPEUTICS, For: Mar 16 Filed by: DILLY STEPHEN GEORGE 7.5%
4/9 Sangamo Announces Closing of Biogen Collaboration Agreement 6.9%
12/23 Form 8-K SANGAMO THERAPEUTICS, For: Dec 17 6.4%
4/28 Form 4 SANGAMO THERAPEUTICS, For: Apr 25 Filed by: Duraibabu Prathyusha 6.0%
5/15 Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences 5.9%
11/8 Sangamo Therapeutics Announces New Scientific Advisory Board 5.5%
4/2 Form DEF 14A SANGAMO THERAPEUTICS, For: May 18 8.8%
4/17 Form 8-K SANGAMO THERAPEUTICS, For: Apr 13 8.6%
3/16 Sangamo's Partnership With Biogen Is Only One Big Pharma Partnership Based Off Of Pipeline [Seeking Alpha] 8.2%
3/18 Form 4 SANGAMO THERAPEUTICS, For: Mar 16 Filed by: DILLY STEPHEN GEORGE 7.5%
4/9 Sangamo Announces Closing of Biogen Collaboration Agreement 6.9%
12/23 Form 8-K SANGAMO THERAPEUTICS, For: Dec 17 6.4%
4/28 Form 4 SANGAMO THERAPEUTICS, For: Apr 25 Filed by: Duraibabu Prathyusha 6.0%
5/15 Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences 5.9%
11/8 Sangamo Therapeutics Announces New Scientific Advisory Board 5.5%
TOP News Decliners
3/14
Sangamo Therapeutics Inc (NASDAQ: SGMO) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating.
-25.2%
12/9 Sangamo Therapeutics Inc (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at Cowen Inc. -17.4%
5/8 Q1/2019 3/31/2019 EPS -0.410 ZacksConsensus -0.270 ActVsEst (0.140) - Miss -14.8%
2/28 Q4/2019 12/31/2019 EPS 0.040 ZacksConsensus -0.310 ActVsEst 0.350 - Beat -8.4%
8/7 Sangamo Therapeutics Reports Second Quarter 2019 Financial Results -6.1%
3/2 AbbVie Is A Notable Coronavirus Responder — But Is ABBV Stock A Buy? [Investor's Business Daily] -6.0%
4/21 Mogrify and Sangamo Announce Collaboration and Exclusive License Agreement for Mogrify’s iPSC- and ESC-Derived Regulatory T Cells -5.9%
4/2 Sangamo Therapeutics Inc (NASDAQ: SGMO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -5.3%
1/25 Sangamo Therapeutics Inc (NASDAQ: SGMO) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -4.9%
9/30 Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer -4.8%
12/9 Sangamo Therapeutics Inc (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at Cowen Inc. -17.4%
5/8 Q1/2019 3/31/2019 EPS -0.410 ZacksConsensus -0.270 ActVsEst (0.140) - Miss -14.8%
2/28 Q4/2019 12/31/2019 EPS 0.040 ZacksConsensus -0.310 ActVsEst 0.350 - Beat -8.4%
8/7 Sangamo Therapeutics Reports Second Quarter 2019 Financial Results -6.1%
3/2 AbbVie Is A Notable Coronavirus Responder — But Is ABBV Stock A Buy? [Investor's Business Daily] -6.0%
4/21 Mogrify and Sangamo Announce Collaboration and Exclusive License Agreement for Mogrify’s iPSC- and ESC-Derived Regulatory T Cells -5.9%
4/2 Sangamo Therapeutics Inc (NASDAQ: SGMO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -5.3%
1/25 Sangamo Therapeutics Inc (NASDAQ: SGMO) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -4.9%
9/30 Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer -4.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: